Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/finding-new-lanes-chimeric-antigen-receptor-car-t-cells-for-myeloid-J0vY4A3jTM
References (88)
-
M Konopleva, I Rissling, M Andreeff (2000)
Human CD38 and Related Molecules -
Tong Zhang, A. Barber, C. Sentman (2006)
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.Cancer research, 66 11
-
Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia -
Diogo Gomes-Silva, Erden Atilla, Pinar Atilla, Feiyan Mo, H. Tashiro, Madhuwanti Srinivasan, P. Lulla, R. Rouce, J. Cabral, C. Ramos, M. Brenner, M. Mamonkin (2019)
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.Molecular therapy : the journal of the American Society of Gene Therapy, 27 1
-
J. Sakamoto, K. Furukawa, C. Cordon-Cardo, B. Yin, W. Rettig, H. Oettgen, L. Old, K. Lloyd (1986)
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines.Cancer research, 46 3
-
D. Sallman, J. Brayer, Elizabeth Sagatys, C. Lonez, E. Breman, S. Agaugué, B. Verma, D. Gilham, F. Lehmann, M. Davila (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patientHaematologica, 103
-
A. Dutour, V. Marin, I. Pizzitola, S. Valsesia-Wittmann, Dean Lee, E. Yvon, H. Finney, A. Lawson, M. Brenner, A. Biondi, E. Biagi, R. Rousseau (2012)
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid LeukemiaAdvances in Hematology, 2012
-
Tetsumi Yoshida, K. Mihara, Y. Takei, K. Yanagihara, T. Kubo, J. Bhattacharyya, C. Imai, T. Mino, Y. Takihara, T. Ichinohe (2016)
All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemiaClinical & Translational Immunology, 5
-
AM Noone, N Howlader, M Krapcho (2017)
SEER Cancer Statistics Review -
Y. Kikushige, T. Miyamoto (2015)
Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid LeukemiaOncology, 89
-
M. Kalos, B. Levine, D. Porter, Sharyn Katz, S. Grupp, A. Bagg, C. June (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 3
-
Xing-qing Pan, Xuan Zheng, Guangfeng Shi, Huaqing Wang, M. Ratnam, Robert Lee (2002)
Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.Blood, 100 2
-
Hardikkumar Jetani, I. García-Cadenas, T. Nerreter, Simone Thomas, Julian Rydzek, J. Meijide, H. Bonig, W. Herr, J. Sierra, H. Einsele, M. Hudecek (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanibLeukemia, 32
-
K. Kita, H. Miwa, K. Nakase, K. Kawakami, T. Kobayashi, S. Shirakawa, I. Tanaka, C. Ohta, H. Tsutani, S. Oguma (1993)
Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma [see comments]Blood, 81
-
N. Hosen, Christopher Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. Krensky, I. Weissman (2007)
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemiaProceedings of the National Academy of Sciences, 104
-
H. Wang, X. Zheng, F. Behm, M. Ratnam (2000)
Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia.Blood, 96 10
-
E. Yuriev, W. Farrugia, A. Scott, P. Ramsland (2005)
Three‐dimensional structures of carbohydrate determinants of Lewis system antigens: Implications for effective antibody targeting of cancerImmunology and Cell Biology, 83
-
Joana Murad, Susanne Baumeister, L. Werner, H. Daley, H. Trébéden‐Nègre, J. Reder, C. Sentman, D. Gilham, F. Lehmann, S. Snykers, M. Sentman, T. Wade, Adam Schmucker, M. Fanger, G. Dranoff, J. Ritz, S. Nikiforow (2018)
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Cytotherapy, 20 7
-
J. Petrov, M. Wada, K. Pinz, Lulu Yan, Kevin Chen, X. Shuai, Hua Liu, Xi Chen, Lai-han Leung, H. Salman, N. Hagag, Fang Liu, Xun Jiang, Yupo Ma (2018)
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemiaLeukemia, 32
-
S Pratap, W Zhao, T Ho, J Zhao (2018)
Generation and characterization of FLT3 ligand?containing chimeric antigen receptor (CAR) T?lymphocytes. In Pediatric Blood & Cancer, 65
-
B. Savoldo, C. Ramos, E. Liu, M. Mims, M. Keating, G. Carrum, R. Kamble, C. Bollard, A. Gee, Z. Mei, Hao Liu, B. Grilley, C. Rooney, H. Heslop, M. Brenner, G. Dotti (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.The Journal of clinical investigation, 121 5
-
Targeting FLT 3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia -
M. Graf, K. Hecht, S. Reif, R. Pelka‐Fleischer, K. Pfister, H. Schmetzer (2004)
Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategiesEuropean Journal of Haematology, 72
-
Z. Kaleem, E. Crawford, M. Pathan, L. Jasper, M. Covinsky, Lawrence Johnson, Lawrence Johnson, G. White (2003)
Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.Archives of pathology & laboratory medicine, 127 1
-
(2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory PRATAP AND ZHAO 7 of 9 PRATAP AND ZHAO 7 of 9 acute myeloid leukemia patient -
(2007)
Weissman IL CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia -
Y. Kikushige, T. Shima, Shin-ichiro Takayanagi, S. Urata, T. Miyamoto, H. Iwasaki, K. Takenaka, T. Teshima, Toshiyuki Tanaka, Y. Inagaki, K. Akashi (2010)
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.Cell stem cell, 7 6
-
R. Majeti, M. Chao, Ash Alizadeh, W. Pang, S. Jaiswal, Kenneth Gibbs, N. Rooijen, I. Weissman (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 138
-
Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to Ctype lectin-like molecule 1. Mol Ther -
J. Hilpert, L. Grosse‐Hovest, F. Grünebach, C. Buechele, Tina Nuebling, Tobias Raum, A. Steinle, H. Salih (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell ResponsesThe Journal of Immunology, 189
-
K. Minagawa, M. Jamil, M. Al-Obaidi, L. Pereboeva, D. Salzman, H. Erba, L. Lamb, R. Bhatia, S. Mineishi, A. Stasi (2016)
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaPLoS ONE, 11
-
S. Galli, I. Zlobec, C. Schürch, A. Perren, A. Ochsenbein, Y. Banz (2015)
CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis.Leukemia research, 39 7
-
S. Nikiforow, L. Werner, Joana Murad, M. Jacobs, L. Johnston, Sarah Patches, Randie White, H. Daley, H. Negre, J. Reder, C. Sentman, T. Wade, Adam Schmucker, F. Lehmann, S. Snykers, Rachel Allen, Heidi Dipietro, Kristen Cummings, I. Galinsky, N. Munshi, R. Schlossman, R. Stone, D. Neuberg, R. Soiffer, G. Dranoff, J. Ritz, Susanne Baumeister (2016)
Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple MyelomaBlood, 128
-
L. Terstappen, M. Safford, S. Könemann, M. Loken, K. Zurlutter, T. Büchner, W. Hiddemann, B. Wörmann (1992)
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.Leukemia, 6 1
-
E. Drent, R. Groen, W. Noort, M. Themeli, J. Bueren, P. Parren, J. Kuball, Z. Sebestyén, Huipin Yuan, J. Bruijn, N. Donk, A. Martens, H. Lokhorst, T. Mutis (2015)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaHaematologica, 101
-
Walid Warda, F. Larosa, Mathieu Rocha, Rim Trad, E. Deconinck, Z. Fajloun, Cyril Faure, D. Caillot, Marius Moldovan, S. Valmary-Degano, S. Biichle, É. Daguindau, F. Garnache-Ottou, S. Tabruyn, O. Adotévi, M. Deschamps, C. Ferrand (2018)
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.Cancer research, 79 3
-
B. Verma, P. Aftimos, A. Awada, J. Machiels, J. Brayer, D. Sallman, T. Kerre, K. Odunsi, C. Lonez, D. Gilham, F. Lehmann (2017)
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types.Journal of Clinical Oncology, 35
-
Daniel Lee, J. Kochenderfer, M. Stetler-Stevenson, Yongzhi Cui, Cindy Delbrook, S. Feldman, T. Fry, R. Orentas, M. Sabatino, N. Shah, S. Steinberg, D. Stroncek, Nicholas Tschernia, C. Yuan, Hua Zhang, Ling Zhang, S. Rosenberg, A. Wayne, C. Mackall (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 385
-
K. Akashi (2015)
TIM-3 Is a Novel Therapeutic Target for Eradicating Acute Myelogenous Leukemia Stem Cells -
S. Kenderian, M. Ruella, O. Shestova, M. Klichinsky, Vania Aikawa, J. Morrissette, J. Scholler, Decheng Song, D. Porter, M. Carroll, C. June, S. Gill (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaLeukemia, 29
-
Yoriko Saito, H. Kitamura, A. Hijikata, Mariko Tomizawa-Murasawa, Satoshi Tanaka, S. Takagi, N. Uchida, Nahoko Suzuki, Akiko Sone, Y. Najima, H. Ozawa, A. Wake, S. Taniguchi, L. Shultz, O. Ohara, F. Ishikawa (2010)
Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2
-
(2015)
CD 33 - specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid -
E. Laborda, Magdalena Mazagova, Sida Shao, Xinxin Wang, Herlinda Quirino, A. Woods, Eric Hampton, D. Rodgers, Chan Kim, P. Schultz, T. Young (2017)
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid LeukemiaInternational Journal of Molecular Sciences, 18
-
M. Konopleva, I. Rissling, M. Andreeff (2000)
CD38 in hematopoietic malignancies.Chemical immunology, 75
-
Wei Zhang, Brett Stevens, E. Budde, S. Forman, C. Jordan, E. Purev (2017)
Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic SyndromeBlood, 130
-
E. Torlak, Mana Taghdiri, Greg Dennis, Joseph Near (2013)
Applications and extensions of Alloy: past, present and futureMathematical Structures in Computer Science, 23
-
S. Florian, K. Sonneck, A. Hauswirth, M. Krauth, G. Schernthaner, W. Sperr, P. Valent (2006)
Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignanciesLeukemia & Lymphoma, 47
-
D. Gilliland, J. Griffin (2002)
The roles of FLT3 in hematopoiesis and leukemia.Blood, 100 5
-
A. Mardiros, Cedric Santos, Tinisha McDonald, C. Brown, Xiuli Wang, L. Budde, Lauren Hoffman, B. Aguilar, W. Chang, William Bretzlaff, B. Chang, Mahesh Jonnalagadda, R. Starr, J. Ostberg, M. Jensen, R. Bhatia, S. Forman (2013)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.Blood, 122 18
-
G. Gross, T. Waks, Z. Eshhar (1989)
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences of the United States of America, 86 24
-
M. Chmielewski, H. Abken (2015)
TRUCKs: the fourth generation of CARsExpert Opinion on Biological Therapy, 15
-
A. Barber, Tong Zhang, L. Demars, J. Conejo-Garcia, K. Roby, C. Sentman (2007)
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.Cancer research, 67 10
-
M. Ames, F. Spreafico (1992)
Selected pharmacologic characteristics of idarubicin and idarubicinol.Leukemia, 6 Suppl 1
-
V. Fedorov, M. Themeli, M. Sadelain (2013)
PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy ResponsesScience Translational Medicine, 5
-
H. Drexler (1996)
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.Leukemia, 10 4
-
H. Ågerstam, N. Hansen, S. Palffy, Carl Sandén, K. Reckzeh, C. Karlsson, H. Lilljebjörn, N. Landberg, M. Askmyr, C. Högberg, M. Rissler, K. Porkka, H. Wadenvik, S. Mustjoki, J. Richter, M. Järås, T. Fioretos (2016)
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.Blood, 128 23
-
Christopher Chien, C. Sauter, Kazusa Ishii, S. Nguyen, F. Shen, S. Tasian, Wei-zao Chen, D. Dimitrov, T. Fry (2016)
Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid LeukemiaBlood, 128
-
Adrienne Long, Waleed Haso, J. Shern, Kelsey Wanhainen, Meera Murgai, M. Ingaramo, Jillian Smith, Alec Walker, M. Kohler, Vikas Venkateshwara, R. Kaplan, George Patterson, T. Fry, R. Orentas, C. Mackall (2015)
4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen ReceptorsNature medicine, 21
-
Quan-shun Wang, Yao Wang, Hai-yan Lv, Qing-wang Han, Hui Fan, Bo Guo, Li-li Wang, W. Han (2015)
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Molecular therapy : the journal of the American Society of Gene Therapy, 23 1
-
Lichao Chen, H. Mao, Jianying Zhang, J. Chu, S. Devine, M. Caligiuri, Jianhua Yu (2017)
Targeting FLT3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid LeukemiaLeukemia, 31
-
(2018)
Generation and characterization of FLT3 ligand-containing chimeric antigen receptor (CAR) T-lymphocytes -
S. Peinert, H. Prince, H. Prince, P. Guru, M. Kershaw, Mark Smyth, Mark Smyth, J. Trapani, J. Trapani, Peter Gambell, Simon Harrison, Andrew Scott, F. Smyth, Phillip Darcy, K. Tainton, P. Neeson, David Ritchie, David Ritchie, D. Hönemann (2010)
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigenGene Therapy, 17
-
Rachel Lynn, M. Poussin, A. Kalota, Yang Feng, P. Low, D. Dimitrov, D. Powell (2015)
Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.Blood, 125 22
-
V. Marin, I. Pizzitola, Valentina Agostoni, G. Attianese, H. Finney, A. Lawson, M. Pule, R. Rousseau, A. Biondi, E. Biagi (2010)
Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptorsHaematologica, 95
-
Miriam Kim, Kyung-Rok Yu, S. Kenderian, M. Ruella, Shirley Chen, Tae-Hoon Shin, Aisha AlJanahi, D. Schreeder, M. Klichinsky, O. Shestova, M. Kozlowski, K. Cummins, Xinhe Shan, M. Shestov, A. Bagg, J. Morrissette, P. Sekhri, C. Lazzarotto, K. Calvo, D. Kuhns, R. Donahue, G. Behbehani, S. Tsai, C. Dunbar, S. Gill (2018)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid LeukemiaCell, 173
-
K. Mihara, K. Yanagihara, M. Takigahira, C. Imai, A. Kitanaka, Y. Takihara, A. Kimura (2009)
Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin LymphomaJournal of Immunotherapy, 32
-
C. Jordan, D. Upchurch, S. Szilvassy, M. Guzman, D. Howard, AL Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D. Rizzieri, S. Luger, G. Phillips (2000)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cellsLeukemia, 14
-
(2017)
MD: National Cancer Institute -
Z. Grada, M. Hegde, Tiara Byrd, D. Shaffer, A. Ghazi, V. Brawley, A. Corder, K. Schönfeld, J. Koch, G. Dotti, H. Heslop, S. Gottschalk, W. Wels, M. Baker, N. Ahmed (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer ImmunotherapyMolecular Therapy. Nucleic Acids, 2
-
A. Barber, Tong Zhang, Christina Megli, Jillian Wu, K. Meehan, C. Sentman (2008)
Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.Experimental hematology, 36 10
-
S. Kenderian, M. Ruella, O. Shestova, M. Klichinsky, Miriam Kim, Craig Soderquist, A. Bagg, Reshma Singh, C. Richardson, R. Young, C. June, S. Gill (2016)
Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T CellsBlood, 128
-
Patrick Hwu, G. Shafer, J. Treisman, Daniel Schindler, Gideon Gross, R. Cowherd, Steven Rosenberg, Zelig Eshhar (1993)
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chainThe Journal of Experimental Medicine, 178
-
D. Ritchie, P. Neeson, P. Neeson, A. Khot, S. Peinert, T. Tai, K. Tainton, Karen Chen, M. Shin, D. Wall, D. Wall, D. Hönemann, Peter Gambell, D. Westerman, J. Haurat, J. Westwood, J. Westwood, A. Scott, Lucy Kravets, M. Dickinson, J. Trapani, J. Trapani, M. Smyth, M. Smyth, P. Darcy, P. Darcy, M. Kershaw, M. Kershaw, H. Prince (2013)
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.Molecular therapy : the journal of the American Society of Gene Therapy, 21 11
-
H. Salih, Holger Antropius, Friederike Gieseke, S. Lutz, L. Kanz, H. Rammensee, A. Steinle (2003)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.Blood, 102 4
-
C. O'Hear, J. Heiber, Ingo Schubert, G. Fey, T. Geiger (2015)
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemiaHaematologica, 100
-
(2016)
Therapeutics, targets, and chemical biology. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors -
R. Paredes-Aguilera, L. Romero‐Guzman, N. López-Santiago, Lenny Burbano‐Ceron, Ofelia Monte, S. Nieto‐Martinez (2001)
Flow cytometric analysis of cell‐surface and intracellular antigens in the diagnosis of acute leukemiaAmerican Journal of Hematology, 68
-
J. Ross, Hui Wang, F. Behm, P. Mathew, Marietta Wu, R. Booth, M. Ratnam (1999)
Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemiaCancer, 85
-
L. Muñoz, J. Nomdedéu, O. López, M. Carnicer, M. Bellido, A. Aventín, S. Brunet, J. Sierra (2001)
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.Haematologica, 86 12
-
Jinghua Wang, Siyu Chen, Wei Xiao, Wende Li, Liang Wang, Shuo Yang, Weida Wang, Liping Xu, Shuangye Liao, Wen-jian Liu, Yang Wang, Na-wei Liu, Jianeng Zhang, X. Xia, Tiebang Kang, Gong Chen, Xiuyu Cai, Han Yang, Xing Zhang, Yue Lu, P. Zhou (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemiaJournal of Hematology & Oncology, 11
-
A. Hombach, H. Abken (2011)
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28‐OX40 signallingInternational Journal of Cancer, 129
-
D. Song, Qunrui Ye, C. Carpenito, M. Poussin, Li-ping Wang, C. Ji, M. Figini, C. June, G. Coukos, D. Powell (2011)
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).Cancer research, 71 13
-
Yi Luo, Lung-Ji Chang, Yong-xian Hu, L. Dong, G. Wei, He Huang (2015)
First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid LeukemiaBlood, 126
-
S. Gill, S. Tasian, M. Ruella, O. Shestova, Yong Li, D. Porter, M. Carroll, G. Danet-Desnoyers, J. Scholler, S. Grupp, C. June, M. Kalos (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.Blood, 123 15
-
Ying Wang, Yingxi Xu, Saisai Li, Jia Liu, Y. Xing, H. Xing, Z. Tian, K. Tang, Q. Rao, Min Wang, Jianxiang Wang (2018)
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cellsJournal of Hematology & Oncology, 11
-
M. Ruella, S. Kenderian, O. Shestova, M. Klichinsky, J. Melenhorst, M. Wasik, S. Lacey, C. June, S. Gill (2017)
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasmsLeukemia, 31
-
I. Pizzitola, Fernando Anjos-Afonso, K. Rouault-Pierre, F. Lassailly, Sarah Tettamanti, O. Spinelli, A. Biondi, E. Biagi, D. Bonnet (2014)
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivoLeukemia, 28
-
H. Tashiro, T. Sauer, T. Shum, Kathan Parikh, M. Mamonkin, Bilal Omer, R. Rouce, P. Lulla, C. Rooney, S. Gottschalk, M. Brenner (2017)
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.Molecular therapy : the journal of the American Society of Gene Therapy, 25 9
- Publisher
- Wiley
- Copyright
- © 2020 Wiley Periodicals, Inc.
- eISSN
- 2573-8348
- DOI
- 10.1002/cnr2.1222
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Cancer Reports – Wiley
Published: Apr 1, 2020
Keywords: ; ; ; ; ;